Donghui Cui
Merck & Co.
17 Papers
296 Citations
Donghui Cui is an academic researcher from Merck & Co.. The author has contributed to research in topics: Metabolite & Dasatinib. The author has an hindex of 15, co-authored 17 publications.
Chat about Author
Papers
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
Thomayant Prueksaritanont,Xiaoyan Chu,Christopher R. Gibson,Donghui Cui,Ka Lai Yee,Jeanine E. Ballard,Tamara D. Cabalu,Jerome Hochman +7 more
TL;DR: The need for conducting DDI studies on a case-by-case basis using a holistic scientifically based interrogative approach is conveyed and the need for additional research to fill in knowledge gaps in these areas where the science is rapidly evolving to better ensure the safety and efficacy of new therapeutic agents is communicated.
232
Metabolism and disposition of dasatinib after oral administration to humans.
Lisa J. Christopher,Donghui Cui,Chiyuan Wu,Roger T. Luo,James Manning,Samuel J. Bonacorsi,Michael W. Lago,Alban Allentoff,Francis Y. Lee,Betty McCann,Susan Galbraith,Donald P. Reitberg,Kan He,Anthony Barros,Anne Blackwood-Chirchir,W. Griffith Humphreys,Ramaswamy A. Iyer +16 more
TL;DR: The exposures of pharmacologically active metabolites M4, M5, M6, M20, and M24 in patients, along with their cell-based IC50 for Src and Bcr-Abl kinase inhibition, suggested that these metabolites were not expected to contribute significantly toward in vivo activity.
199
Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics
Lifei Wang,Lisa J. Christopher,Donghui Cui,Wenying Li,Ramaswamy A. Iyer,W. Griffith Humphreys,Donglu Zhang +6 more
TL;DR: Multiple in vitro experiments showed that dasatinib was predominately metabolized by CYP3A4, and suggested that the formation of M20 was more efficient than other metabolites.
80
Patent
Dihydropyrimidines and uses thereof
Donghui Cui,Margaret R. Davis,Michael Dunn,Benjamin Evans,Hanumath P. Kari,Bharat Lagu,Dhanapalan Nagarathnam,Kamlesh P. Vyas,Kanyin Zhang +8 more
- 16 Nov 1995
TL;DR: In this paper, a dihydropyrimidine compound which is a selective antagonist for human α-1A receptors was used for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, and for the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where the antagonism of the α1A receptor may be useful.
45
Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys
Lisa J. Christopher,Donghui Cui,Wenying Li,Anthony Barros,Vinod Arora,Haiying Zhang,Lifei Wang,Donglu Zhang,James Manning,Kan He,Anthony M. Fletcher,Marc Ogan,Michael W. Lago,Samuel J. Bonacorsi,W. Griffith Humphreys,Ramaswamy A. Iyer +15 more
TL;DR: Across species, dasatinib underwent in vitro oxidative metabolism to form five primary oxidative metabolites and secondary metabolites formed from combinations of the oxidative pathways and conjugated metabolites of dAsatinib and its oxidative metabolites were also observed in hepatocytes incubations.
43